Achieving complete remission (CR) in childhood relapsed/refractory acute lymphoblastic leukaemia (ALL) is a difficult task. Bortezomib, a proteasome inhibitor, has in vitro activity against ALL blasts. A phase I-II trial, reported by the Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) consortium, demonstrated that bortezomib with chemotherapy has acceptable toxicity and remarkable activity in patients with relapsed ALL failing 2-3 previous regimens. We evaluated bortezomib in combination with chemotherapy in 30 and 7 children with B-cell precursor (BCP) and T-cell ALL, respectively. Bortezomib (1Á3 mg/m 2 /dose) was administered intravenously on days 1, 4, 8, and 11. Chemotherapy agents were the same as those used in the TACL trial, consisting of dexamethasone, doxorubicin, vincristine and pegylated asparaginase. Three patients (8Á1%) died due to infections. Twenty-seven patients (72Á9%) achieved CR or CR with incomplete platelet recovery (CRp). Fourteen had minimal residual disease (MRD) lower than 0Á1%. Twenty-two of 30 BCP-ALL patients (73Á3%) and 5/7 patients (71%) with T-cell ALL achieved CR/ CRp. The 2-year overall survival (OS) is 31Á3%; CR/CRp patients with an MRD response had a remarkable 2-year OS of 68Á4%. These data confirm that the combination of bortezomib with chemotherapy is a suitable/effective option for childhood relapsed/refractory ALL.
Despite the remarkable improvement in the prognosis of childhood acute lymphoblastic leukaemia (ALL) over the past few decades (Pui & Evans, 2006) , achievement of complete remission (CR) in relapsed/refractory (R/R) ALL is hampered by a low response rate and substantial toxicity (Cooper & Brown, 2015) . Moreover, as in patients reaching a new CR, the final outcome of paediatric patients with R/R ALL remains unsatisfactory, with the long-term overall survival (OS) ranging between 5% and 50% for patients in first or subsequent relapse (Locatelli et al, 2012) . In particular, for children with B-cell precursor (BCP)ALL experiencing isolated bone marrow (BM) relapse or first relapse after short remission duration, and for those with relapsed T-cell lineage ALL, the probability of 5-year leukaemia-free (LFS) survival does not exceed 30%, even when they receive allogeneic haematopoietic stem cell transplantation (HSCT) (Parker et al, 2010; Tallen et al, 2010; Eckert et al, 2015) .
The most frequent causes of treatment failure for children with relapsed ALL are either resistance to second-line therapy or subsequent BM relapse (Paganin et al, 2008; Tallen et al, 2010; Eckert et al, 2015) . Indeed, overall, re-induction chemotherapy after first relapse is successful at inducing CR in only 80-85% of patients (Parker et al, 2010; Tallen et al, 2010; Locatelli et al, 2012; Eckert et al, 2015) . The Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) consortium reported low remission rates of 44%, 27% and 12% for third, fourth and further therapeutic attempts, respectively (Ko et al, 2010) . Moreover, the outcome of children and adolescents with relapsed ALL and non-response to initial salvage therapy is so far miserable, even when therapies with curative intent are employed (von Stackelberg et al, 2011) .
Standard salvage regimens for relapsed ALL are still largely based on different combinations of the same agents used in frontline therapy in varying doses and schedules. However, also because few randomized trials comparing different re-induction regimens in risk-stratified children with relapsed ALL have been conducted so far (Parker et al, 2010; Tallen et al, 2010; Locatelli et al, 2012) , it remains unclear whether any re-induction combination in use today is significantly superior to any other. This suggests that novel approaches are needed for improving CR rates and blast clearance in these patients, and clinical trials are currently ongoing to evaluate the safety and efficacy of adding new agents for re-induction chemotherapy. In particular, recently, some studies have investigated, with promising results, or are investigating alternative treatments for BCP-ALL, including the anti-CD22 antibodydrug conjugate inotuzumab ozogamicin (Kantarjian et al, 2016) , the bispecific T-cell engager monoclonal antibody blinatumomab (Topp et al, 2015) and CD19-specific chimeric antigen receptor T-cell technology (Grupp et al, 2013) .
The proteasome inhibitors constitute a growing group of compounds currently under clinical use or investigation. Bortezomib (Velcade©, JANSSEN-CILAG INTERNATIONAL NV Beerse, Belgium) was the first proteasome inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of newly diagnosed multiple myeloma (MM), R/R MM and mantle cell lymphoma (Kane et al, 2006 (Kane et al, , 2007 . Despite the fact that the anticancer activity of bortezomib is still not completely elucidated, it is clear that multiple mechanisms are involved. Although bortezomib displays only modest single agent activity in children with acute leukemia, in vitro, bortezomib is synergic with dexamethasone and additive with asparaginase, vincristine, doxorubicin, and cytarabine (Horton et al, 2006 ). Anecdotally, a child with ALL who previously experienced multiple relapses had a transient clinical response to the administration of bortezomib and dexamethasone (Brown et al, 2004) . A phase I study by Attar et al (2008) suggested that bortezomib is well tolerated in combination with idarubicin and cytarabine in acute myeloid leukaemia (AML) and, when combined with valproic acid (a histone deacetylase inhibitor), the drug was shown to have in vitro promising activity against AML blasts (Wang et al, 2011; Nie et al, 2012) . Recently, Buontempo et al (2016) demonstrated also that Casein Kinase 2 (CK2) inhibition could be useful in combination with bortezomib as a novel therapeutic strategy in both T-cell and BCP-ALL. Moreover, two TACL phase I and II studies showed that a combination of bortezomib with vincristine, dexamethasone, pegylated Lasparaginase and doxorubicin (VXLD) is active and has acceptable toxicity in children with R/R BCP-ALL (Messinger et al, 2010 (Messinger et al, , 2012 . Overall, these data indicate that the combination of bortezomib with cytotoxic agents routinely used in the treatment of acute leukaemia has clinical efficacy, which requires confirmation and further investigation.
This report describes the results of a monocentric study carried out in paediatric patients with R/R BCP ALL or T-cell ALL who received the combination of bortezomib with VXLD, according to the scheme published by the TACL group (Messinger et al, 2010 (Messinger et al, , 2012 , with the aim of re-inducing a new CR.
Patients and methods

Study group
Patients aged 15 years or less at time of diagnosis and 21 years or less at time of treatment were included in the study. Eligibility criteria were a performance status ≤2 according to Eastern Cooperative Oncology Group criteria (Oken et al, 1982) and absence of any active infection at time of evaluation for enrollment. Other inclusion criteria were: patient serum bilirubin ≤29 upper limit of normal (ULN) for age, aspartate transaminase and alanine transaminase ≤59 ULN and serum creatinine <29 ULN.
Disease status of the patients was assessed by history, clinical evaluation, and morphological, cytogenetic and immunophenotyping analysis of both BM and peripheral blood cells. Patients who had previously received allogeneic HSCT were eligible, as long as they were not being treated for active graft-versus-host disease (GvHD). Patients' parents gave written informed consent before treatment. This study was conducted according to guidelines active at the Bambino Ges u Children's Hospital, Rome (Italy), and in accordance with the principles of the Helsinki Declaration.
Treatment plan
The scheme employed was the same as that used in the TACL trial (Messinger et al, 2010 (Messinger et al, , 2012 . In particular, bortezomib (1Á3 mg/m 2 /dose) was administered intravenously on days 1, 4, 8 and 11. Dexamethasone 10 mg/m 2 /day was given either orally or intravenously for 14 consecutive days. Doxorubicin 60 mg/m 2 was given intravenously on day 1. Vincristine 1Á5 mg/m 2 /dose (2 mg maximum dose) was administered intravenously on days 1, 8, 15 and 22. Pegylated asparaginase 2500 U/m 2 /dose was given intravenously weekly for 4 doses. All patients received intrathecal (IT) methotrexate on day 1. Patients without central nervous system (CNS) ALL involvement were given a second IT injection of methotrexate on day 15. Patients with CNS involvement received additional IT triple-chemotherapy, consisting of methotrexate, methylprednisolone and cytarabine on days 8, 15 and 22. Responding patients were offered allogeneic HSCT if a suitable donor was immediately available or were given consolidation courses of chemotherapy including multiple agents active against ALL, which were chosen according to the treating physician's preference and previous treatment.
Response criteria
Response to treatment was assessed using morphological, cytogenetic and immunophenotyping analysis on day 29. If, at that time, the marrow was hypoplastic, a new BM aspiration and complete blood count (CBC) were performed weekly until recovery or progression. CR was defined as follows: absence of physical signs of leukaemia or detectable leukaemia cells on peripheral blood smear; BM with active haematopoiesis and <5% leukaemia cells; absolute neutrophil count (ANC) >1 9 10 9 /l, and platelet count >100 9 10 9 /l; normal cerebrospinal fluid findings.
Complete response without platelet recovery (CRp) was defined as M1 BM (<5% bone marrow blasts) with no circulating blasts or extramedullary disease and recovery of ANC (>1 9 10 9 /l) but insufficient recovery of platelets (<100 9 10 9 /l). Persistent disease (PD) was defined as a BM with more than 5% leukaemia cells, development of new sites of extramedullary disease, or clinical evidence of PD, with or without neutrophil and platelet recovery. The assessment of minimal residual disease (MRD) was performed on BM samples by flow cytometry. BM aplasia was defined as the presence in the peripheral blood of an ANC <0Á2 9 10 9 /l and a platelet count <20 9 10 9 /l for at least 3 consecutive days.
The National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE v4.03) were used to evaluate the severity of adverse events recorded on the treating physician's assessement (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf; Accessed June 14, 2010).
Patient monitoring
Pre-treatment evaluations included physical examination, concomitant medication assessment, BM aspirate, lumbar puncture and high-resolution CT scan of the head, chest, abdomen and pelvis. In addition, blood was drawn for serum chemistry, CBC, evaluation of hepatitis viruses and human immunodeficiency virus antibodies. Quantification of adenovirus DNA, Epstein-Barr virus DNA and cytomegalovirus DNA by polymerase chain reaction assay and evaluation of serum galactomannan antigen index were performed at least once a week during the first month. Echocardiogram and electrocardiogram were performed before starting chemotherapy.
Supportive therapy
All patients were initially hospitalized for re-induction treatment, and supportive therapy was administered according to institutional protocols. Given the reported high frequency of infectious complications occurring during treatment (Messinger et al, 2010 (Messinger et al, , 2012 and the prevalence of disease-related neutropenia, prophylactic antibiotics (piperacillin-tazobactam) were administered to all children. Broad-spectrum antibiotics were further added if a patient became febrile. All patients were given acyclovir for prevention of herpesvirus infection. Voriconazole or liposomal amphotericin (3 mg/kg twice a week) was administered for preventing fungal infections until neutrophil recovery. Antifungal therapy against both yeasts and moulds was modified if there was clinical evidence of proven/probable fungal infection. Recombinant human granulocyte-colony stimulating factor (G-CSF) at the dosage of 5-10 lg/kg/day was used only in case of occurrence of documented sepsis in a neutropenic patient.
Statistical analysis
Quantitative variables were reported as median value and range, while categorical variables were expressed as absolute value and percentage. Disease-free survival (DFS) was defined as the time from study enrolment to the date of first event or last follow-up. Events were relapse, second neoplasm or death from any cause. Overall survival (OS) was defined as the time from study enrolment to death from any cause or last follow-up. The Kaplan-Meier method was used to estimate DFS and OS probabilities. Differences between groups were compared with the log-rank test. P < 0Á05 were considered to be statistically significant and reported in detail. Patient data were updated in August 2016. Statistical analysis was performed using EZR version 1.32 (Saitama Medical Centre, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (Kanda, 2013) .
Results
Patients and treatment
Between February 2012 and June 2016, 37 paediatric patients with R/R ALL were given the treatment detailed above (see Treatment plan) at the Haematology/Oncology Department of the IRCCS Bambino Ges u Children's Hospital, Rome, Italy; 30 had BCP and 7 T-cell ALL (2 of them had early T-cell precursor ALL). Patient's characteristics are detailed in Table I . The cohort included 20 males and 17 females, median age at time of latest leukaemia relapse being 10Á3 years (2Á6-21). Four patients had CNS involvement at diagnosis, while 8/37 experienced combined BM and extramedullary relapse (6 CNS, 1 kidney and 1 gut, respectively). Fifteen children had previously received HSCT, the median time elapsing from HSCT being 218 days (range, 116-1075). Fifteen of the 37 patients (41%) included in the study, had received more than 2 lines of therapy, including clofarabine and blinatumomab, before being enrolled in this study and 7 had refractory disease. The median BM blast percentage in the overall population at time of treatment was 65% (range, 32-95%).
Toxicity
Haematological and non-haematological toxicities are listed in Table II In our cohort, three septic deaths associated with multisystem organ failure were recorded; all were due to fungal infections (the pathogens demonstrated in blood culture samples were: Dipodascus capitatus, Geotrichum capitatum and Sporopachidermia lactativora). All those patients had received either high-dose liposomal amphotericin (5 mg/kg/ day) or voriconazole and G-CSF to accelerate neutrophil recovery. Notably, the severe fungal sepsis developed during the grade 3-4 neutropenic period, and death occurred at a median time of 30 days (range 17-39) from the start of treatment.
During the fourth week of treatment another two patients developed sepsis due to Candida parapsilosis and Stenotrophomonas maltophilia, respectively, which resolved under appropriate treatment. Another patient experienced Klebsiella pneumoniae sepsis on day 13 of the treatment schedule. Intensive combined antibiotic therapy combined with G-CSF was started, and Day 15 chemotherapy was postponed until neutrophil recovery. The patient successfully overcame the sepsis and achieved CR.
The other most common adverse events were neurological complications. One child transiently developed central ataxia, disorientation, headache and dysarthria, which resolved completely within a few days without sequels. Five patients (14Á7%) experienced peripheral motor and sensory neuropathy; only one of them had grade 4 sensory neuropathy. All these children had received all 4 doses of bortezomib before the onset of peripheral neuropathy. Neuropathy completely resolved in all these patients using gabapentin, vitamin B1 and B6 supplementation and adequate neuro-physiotherapy.
Metabolic abnormalities, including hypokalaemia, hyponatraemia and hypocalcaemia, were recorded in 15/37 (40Á5%) patients. Nausea, vomiting, or diarrhoea were adequately controlled/prevented with appropriate therapy and never reached grade 3. Low fibrinogen levels and coagulation abnormalities were common, occurring in 83Á7% of patients (31/37), but were never higher than grade 2-3. We did not observe pulmonary toxicity, described after bortezomib use in adults (Miyakoshi et al, 2006) . Thirteen patients (35%) developed BM aplasia during treatment. The median period of hospitalization was 29 days (range 18-51).
Response and outcome
Twenty-three and 4 out of the 37 patients achieved CR (62%) and CRp (10Á8%), respectively, leading to an overall response rate of 72Á9%. Fourteen of them (52%) had MRD <0Á1%, while the remaining 13 patients had MRD levels of between 0Á15% and 2Á2%. Seven children had resistant disease, resulting in a failure rate of 18Á9%. Three children died during the chemotherapy-induced BM aplasia phase, before adequate evaluation of response/disease status could be determined. Interestingly, in our cohort, not only patients with BCP ALL had a good outcome (22/30, 73Á3% CR rate), but also those with T-cell ALL responded well to this combination of drugs (5/7, 71Á4% CR rate). The CR/CRp rate of patients who had or had not received allogeneic HSCT before being enrolled in the study was 60% and 81Á8%, respectively, while that of patients treated as third-line therapy was 75%. Patients with refractory disease had a CR/CRp rate of 66%, which did not statistically differ from that of patients treated without a documented refractoriness to the last previous treatment. Twenty-three of these patients had long-lasting CR, enabling 18 of them to receive allogeneic HSCT [10 from a human leucocyte antigen (HLA)-haploidentical parent, 5 from a matched unrelated donor and 3 from an HLA-identical sibling]. With a median follow-up of 364 days (range 45-1089), the 2-year OS and DFS were 31Á3% (95% confidence interval, CI, 15Á3-48Á7, Fig 1A) and 27Á7% (95% CI 12Á4-45Á4, Fig 1B) , respectively. Children with T-cell lineage ALL had a 2-year OS [53Á6% (95% CI 13Á2-82Á5)] comparable to that of BCP ALL patients [24Á4% (95% CI 8Á8-44Á1)] (P = not significant, Fig 2) . Patients who achieved CR after this course of chemotherapy experienced a better OS compared to those who did not respond (see also Fig 3A for details) . Among the 27 responding patients, the OS probability of patients who reached a MRD level below 0Á1% was significantly better compared with those who did not, being 68Á4% (95% CI 35Á9-86Á8) vs. 0% (P = 0Á01, Fig 3B) . In patients responding to treatment, the median time to reach a platelet count >20 9 10 9 /l and an ANC >0Á5 9 10 9 /l were 21 (range, 12-43) and 28 days (range, 14-41), respectively.
Discussion
This study confirms that, for children with R/R BCP-ALL, the combination of bortezomib with vincristine, dexamethasone, pegylated asparaginase and doxorubicin is associated with acceptable organ toxicity and produces a remarkable overall CR rate, as previously described (Messinger et al, 2010 (Messinger et al, , 2012 . Interestingly, our data show that this regimen is effective also in T-cell ALL, as 5 out of the 7 patients with T-ALL enrolled in the study reached CR/CRp. Considering the poor prognosis of relapsed T-ALL (Locatelli et al, 2012) , a response rate of 71Á4% for children with T-cell ALL in this group is promising. The favourable outcome of patients with T-ALL could be explained by the observation that the proteasome inhibitor bortezomib represses the transcription of NOTCH1 and downstream effectors including HES1, GATA3, RUNX3 and nuclear factor-kB (NF-kB) (Espinosa et al, 2010; D'Altri et al, 2011) . Overexpression of the NOTCH1 intracellular domain (NICD) significantly ameliorated bortezomibinduced cytotoxicity against T-ALL cells Koyama et al, 2014) . Drug combination studies revealed that bortezomib had a synergistic or additive effect with key drugs for the treatment of T-ALL, such as dexamethasone, doxorubicin and cyclophosphamide, whose cytotoxic effect was readily abolished by NICD overexpression. Notably, the 2-year OS of patients affected by T-ALL was comparable to that of children with BCP-ALL (see also Fig 2B) .
In view of the low organ toxicity, the combination of bortezomib and VXLD might also be considered for patients who had previously received allogeneic HSCT and/or monoclonal antibodies, such as blinatumomab (Topp et al, 2015) . Twelve out of the 16 (75%) BCP-ALL patients enrolled in this study and who had failed blinatumomab responded to this combination of drugs, with 5 of them achieving a MRD <0Á1%.
Historically, paediatric patients failing 2 or more previous regimens achieved a CR rate of approximately 40% with a variety of multidrug regimens (Gaynon, 2005; Ko et al, 2010) . In the present study, 43Á2% of patients had failed more than 2 previous regimens, including HSCT, as well as novel, effective drugs in ALL, such as clofarabine and blinatumomab; their CR/CRp rate was 75%.
The TACL trials did not measure the MRD of responding patients (Messinger et al, 2010 (Messinger et al, , 2012 ; in our cohort, we found that half of patients who obtained CR/CRp had a MRD level below 0Á1%. This finding is noteworthy, considering that a low MRD level is a pre-requisite for benefiting from subsequent allogeneic HSCT (Bader et al, 2009) . Moreover, in our patients, achievement of MRD response translated into a significantly better probability of 2-year OS (see also Fig 3B) .
Infections were a common event, as would be expected in a heavily pre-treated population with profound and longstanding immune-and myelo-suppression. Based on the occurrence of fungal infections observed in the phase I and II studies published by the TACL group (Messinger et al, 2010 (Messinger et al, , 2012 , we used broad-spectrum antifungal prophylaxis starting from day 1. Despite this prophylaxis and notwithstanding aggressive antifungal treatment started once the infections were diagnosed, 3 patients died of fungal infections. Notably, all fungal sepsis occurred in children who developed chemotherapy-induced BM aplasia. Invasive fungal infections remain an important cause of morbidity and mortality in patients with acute leukaemia (Leventakos et al, 2010) . The complex scenario in which these infections occur, especially in cases of relapsed or refractory disease, creates diagnostic and treatment challenges (Hale et al, 2010) . In particular, new strains of yeasts and moulds like those observed in our population are isolated with increased frequency (Brunetti et al, 2016; Del Principe et al, 2016) . We cannot exclude that the prophylaxis with antibiotics that we used may have contributed to these rare fungal infections (Ben-Ami et al, 2012) . Considering cohort studies published during the past decades, an incidence of fungal infections of about 10% or higher is consistently reported in populations of patients with AML and R/R ALL (Groll et al, 2014) . Overall case-fatality rates of invasive fungal disease in the series analysed were between 20% and 70%, with poorest outcomes in patients with disseminated disease, CNS involvement or persistent neutropenia (Dvorak et al, 2012; Groll et al, 2014) .
As previously described (Richardson et al, 2009; Messinger et al, 2012) and expected, considering that the scheme of treatment includes 2 drugs with known neurotoxicity (vincristine and bortezomib), the other major toxicity was neurotoxicity. Although both sensor and motor neuropathy were transient and resolved under appropriate treatment in our children, we recommend strict monitoring of patients given vincristine with bortezomib, especially when, in addition, they receive voriconazole for mould-active prophylaxis of fungal infections.
Bone marrow aplasia was not seen in both the phase I and II studies conducted by Messinger et al (2010 Messinger et al ( , 2012 . Here, we report that this regimen leads to a non-negligible rate of BM aplasia. Indeed, in our cohort, 13/37 patients had chemotherapy-induced aplasia. In our study, the median time of platelet and ANC recovery was 21 and 28 days, respectively. Such a delay in haematological recovery is not surprising for heavily pre-treated patients. In light of the number of severe infections occurring during the neutropenic period, the use of G-CSF to hasten neutrophil recovery could be considered, especially in febrile patients.
In conclusion, our study indicates that a standard dose of bortezomib 1Á3 mg/m 2 given on days 1, 4, 8 and 11 can be safely combined with an intensive 4-drug re-induction regimen in children with R/R ALL, of both BCP and T-cell lineage. This study also supports further evaluation of bortezomib in children with R/R-ALL, including those experiencing first relapse, or even in newly diagnosed patients at high risk of treatment failure due to either high level of MRD or poor-risk cytogenetics. Considering the high risk of life-threatening/fatal infections in such a vulnerable population, accurate microbiological monitoring and aggressive antibacterial and antifungal prophylaxis/treatment are recommended.
